Cellectar Biosciences (NASDAQ: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company is also developing PDCs for targeted delivery of chemotherapeutics and plans to expand its PDC chemotherapeutic pipeline through in-house and collaborative R&D efforts. For additional information, visit the company’s website at www.cellectarbiosciences.com